MedTrace Logo

Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate Cancer

NCT02453009 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 246

Last updated 2024-05-30

No results posted yet for this study

Summary

The aim of this study is to verify if the addition of enzalutamide to docetaxel is able to improve the disease control in first line CRPC patients.

Conditions

  • Prostatic Neoplasms

Interventions

DRUG

Docetaxel

Pharmaceutical form:solution Route of administration: intravenous

DRUG

Prednisone

Pharmaceutical form:tablet Route of administration: oral

DRUG

Enzalutamide

Pharmaceutical form : soft gelatin capsules Route of administration: oral

Sponsors & Collaborators

  • Santa Chiara Hospital

    lead OTHER

Principal Investigators

  • Orazio Caffo, MD · Santa Chiara Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2018-04-30
Completion
2019-04-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02453009 on ClinicalTrials.gov